{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T19:36:06Z","timestamp":1783107366389,"version":"3.54.6"},"reference-count":28,"publisher":"The Journal of Rheumatology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Although prednisolone (PSL) and immunosuppressants are key drugs for Takayasu arteritis (TA) treatment, there is limited evidence on the optimal PSL dose. The aim of this study was to investigate the correlation between the initial PSL dose and relapse in TA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>We enrolled 105 patients with TA who satisfied the criteria of the Japanese Circulation Society and American College of Rheumatology from 1990 to 2015. The clinical characteristics and outcomes of patients with TA were retrospectively evaluated. The relapse-free period was assessed according to the difference in initial treatments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Relapse was observed in 57 (59.4%) of 96 patients treated with immunosuppressive therapy at diagnosis during a median followup of 56 months. Male sex and younger age of onset were significantly associated with relapse. Although \u2264 30 mg\/day PSL monotherapy was preferably prescribed for patients with lower inflammatory markers, compared with &gt; 30 mg\/day (87.2% vs 52.6%), a significantly higher relapse rate was observed in the \u2264 30 mg\/day group (HR 1.78; p = 0.047). Further, the relapse-free period was longer in patients treated with \u2265 50 mg\/day PSL compared with those treated with \u2264 40 mg\/day PSL. Combination therapy improved the relapse-free period compared with PSL monotherapy in the short term. The initial PSL dose was not associated with adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>A higher dose of PSL was associated with a significant decrease in the relapse rate. The effect of combination therapy on relapse needs to be further investigated. Lower-dose PSL monotherapy is an undesirable strategy for remission induction in TA, despite low disease activity.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.181219","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T13:05:32Z","timestamp":1571144732000},"page":"255-263","source":"Crossref","is-referenced-by-count":31,"title":["Insufficient Use of Corticosteroids without Immunosuppressants Results in Higher Relapse Rates in Takayasu Arteritis"],"prefix":"10.3899","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5995-8609","authenticated-orcid":false,"given":"Tomoyuki","family":"Mutoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6295-3494","authenticated-orcid":false,"given":"Tsuyoshi","family":"Shirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Harigae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2019,5,15]]},"reference":[{"key":"2020020109251885000_47.2.255.1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jaut.2014.01.012","article-title":"Diagnostic and classification criteria of Takayasu arteritis","volume":"48\u20139","author":"de Souza","year":"2014","journal-title":"J Autoimmun"},{"key":"2020020109251885000_47.2.255.2","doi-asserted-by":"crossref","first-page":"5933","DOI":"10.3748\/wjg.v19.i35.5933","article-title":"Crohn\u2019s disease and Takayasu\u2019s arteritis: an uncommon association","volume":"19","author":"Taddio","year":"2013","journal-title":"World J Gastroenterol"},{"key":"2020020109251885000_47.2.255.3","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3109\/14397595.2013.854045","article-title":"Ulcerative colitis is not a rare complication of Takayasu arteritis","volume":"24","author":"Watanabe","year":"2014","journal-title":"Mod Rheumatol"},{"key":"2020020109251885000_47.2.255.4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14397595.2017.1341592","article-title":"Coexistence of Takayasu\u2019s arteritis and ankylosing spondylitis may not be accidental \u2014 is there a need for a new subgroup in the spondyloarthritis family?","volume":"28","author":"Mielnik","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2020020109251885000_47.2.255.5","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.2169\/internalmedicine.0329-17","article-title":"Takayasu arteritis coexisting with sclerosing osteomyelitis","volume":"57","author":"Shirai","year":"2018","journal-title":"Intern Med"},{"key":"2020020109251885000_47.2.255.6","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12309"},{"key":"2020020109251885000_47.2.255.7","doi-asserted-by":"publisher","DOI":"10.3109\/08916934.2015.1027815"},{"key":"2020020109251885000_47.2.255.8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/BOR.0000000000000265","article-title":"Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis","volume":"28","author":"Koster","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"2020020109251885000_47.2.255.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.088351"},{"key":"2020020109251885000_47.2.255.10","unstructured":"Guidelines for management of vasculitis syndrome (JCS 2017 \u2014 in Japanese). [Internet. Accessed August 19, 2019.] Available from: www.j-circ.or.jp\/guideline\/pdf\/JCS2017_isobe_h.pdf"},{"key":"2020020109251885000_47.2.255.11","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-88-0007"},{"key":"2020020109251885000_47.2.255.12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF01744559","article-title":"Medical treatment of Takayasu arteritis","volume":"7","author":"Ito","year":"1992","journal-title":"Heart Vessels Suppl"},{"key":"2020020109251885000_47.2.255.13","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/art.1780330811","article-title":"The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis","volume":"33","author":"Arend","year":"1990","journal-title":"Arthritis Rheum"},{"key":"2020020109251885000_47.2.255.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5273(96)02813-6"},{"key":"2020020109251885000_47.2.255.15","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-120-11-199406010-00004"},{"key":"2020020109251885000_47.2.255.16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket320"},{"key":"2020020109251885000_47.2.255.17","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-11-1108"},{"key":"2020020109251885000_47.2.255.18","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.semarthrit.2017.09.014","article-title":"Long-term outcome of 251 patients with Takayasu arteritis on combination immunosuppressant therapy: single centre experience from a large tertiary care teaching hospital in Southern India","volume":"47","author":"Goel","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2020020109251885000_47.2.255.19","first-page":"S59","article-title":"Takayasu\u2019s arteritis in Turkey \u2014 clinical and angiographic features of 248 patients","volume":"27","author":"Bicakcigil","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"2020020109251885000_47.2.255.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.04.025"},{"key":"2020020109251885000_47.2.255.21","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140664"},{"key":"2020020109251885000_47.2.255.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.20300"},{"key":"2020020109251885000_47.2.255.23","doi-asserted-by":"crossref","unstructured":"Pazzola G Muratore F Pipitone N Crescentini F Cacoub P Boiardi L Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature. Rheumatology 2017 July 18 (E-pub ahead of print).","DOI":"10.1136\/annrheumdis-2017-eular.5158"},{"key":"2020020109251885000_47.2.255.24","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.54.405"},{"key":"2020020109251885000_47.2.255.25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211878"},{"key":"2020020109251885000_47.2.255.26","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker410"},{"key":"2020020109251885000_47.2.255.27","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-155-7-201110040-00005"},{"key":"2020020109251885000_47.2.255.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.10.058"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.181219","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T12:27:50Z","timestamp":1580560070000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.181219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,15]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,1]]},"published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.3899\/jrheum.181219"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.181219","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,15]]}}}